1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma trials Research Report on Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma External Beam Radiation Therapy, Pembrolizumab - Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 17 | 2018-02-01 | 2026-01-13 |
Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Azacitidine (1) · CT-P10 (1) · Cyclophosphamide (1) · Doxorubicin (1) · Hyaluronoglucosaminidase (1) · Magnetic Resonance Spectroscopy (1) · Prednisone (1) · Rituximab (1) · Specimen Handling (1) · Vincristine (1) · cc-486 (1) · deltacortene (1) · pembrolizumab (1) · prednylidene (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2)
Chelsea C Pinnix (1) · Elizabeth A Brem (1)
U10CA180888 (1)